Compare MPLX LP (MPLX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Vertex Pharmaceuticals Incorporated — how do they compare? MPLX LP trades at $56.3 (market cap $58.11B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.2× MPLX LP's market cap, and MPLX LP pays a 7.51% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MPLX | VRTX | |
|---|---|---|
Market Cap | $58.11B | $127.55B |
Volume | 687,483 | 1,487,944 |
Sector | Energy | Health |
52-Week High | $60.51 | $557.96 |
52-Week Low | $47.80 | $407.37 |
Enterprise Value | $83.22B | $121.68B |
Dividend Yield | 7.51% | — |
Typical Hold Time | — | 120 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $56.30, down 1.31% today, with a bearish technical signal and mixed earnings history including a recent Q2 2026 EPS miss. The company maintains strong profitability with a 40.45% net income margin and robust cash flow, supporting a $1.08 dividend. Analyst consensus is bullish with a $63.80 price target, though technical indicators show near-term resistance at $58.
The outlook for MPLX is positive due to its fee-based revenue model, high dividend yield, and analyst support, but risks include energy market volatility and recent earnings misses. Investors may find value in its cash flow stability, though caution is warranted given bearish technical trends and macroeconomic pressures on the energy sector.
Vertex Pharmaceuticals (VRTX) trades at $510.08, up 0.88% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $12B revenue and $4B net income, though recent quarterly earnings show inconsistent performance against expectations. Positive Phase 2b data for inaxaplin in kidney disease highlights pipeline progress beyond cystic fibrosis dominance.
Wall Street maintains strong bullish sentiment with 84% buy ratings and $573.50 consensus target, but risks include competitive pressures and reliance on CF franchise. The stock's premium valuation (P/E 29.31) requires continued execution on pipeline expansion to justify upside potential amid technical resistance near $515.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
